WEEKLY e-ALERT  [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Case Studies
Bayer to Focus More on R&D and Innovation in China(1/20/2020 )  (Premium)
Industry News
Novotech: Asia-Pacific Had A Record Year for Clinical Trials(1/20/2020 )  (Premium)
Chi-Med Reports Positive Surufatinib Phase III SANET-p Study(1/20/2020 )  (free)
Zydus and CMS enter into a License Agreement for Desidustat in Greater China(1/20/2020 )  (Premium)
Regulatory News
NMPA Publicizes List of Reference Formulations for Generic Drug Equivalence Studies (27th Batch)(1/20/2020 )  (Premium)
General Health
National Primary Healthcare Working Conference Highlights Key Tasks in 2020(1/20/2020 )  (Premium)
National Drug Registration and Post-marketing Surveillance Conference Lays Out Key Tasks in 2020(1/20/2020 )  (Premium)
Product/R&D News
China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program(1/20/2020 )  (Premium)
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links